<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Eikelboom, John W.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Data from New Oral Anticoagulants Provide Clues for Future Drug Development</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4-5</style></pages><abstract><style  face="normal" font="default" size="100%">The new oral anticoagulants have delivered promising results in terms of efficacy and safety. However, the data from the many clinical trials that have evaluated the new agents has provided physicians with a wealth of information for future drug development. This article presents five lessons learned from the recent clinical trials that evaluated the novel oral anticoagulant agents, including dabigatran, rivaroxaban, and apixaban.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>